redox balance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It occurs in nearly all living cells, with highest concentrations in liver, kidney, and red blood cells, and exists in reduced (GSH) and oxidized disulfide (GSSG) forms. The cysteine thiol group enables reversible oxidation and reduction reactions. This property makes glutathione a central participant in cellular redox balance. The balance between these forms is often used as an indicator of oxidative stress.
Glutathione synthesis proceeds in two ATP-dependent steps catalyzed by glutamate-cysteine ligase and glutathione synthetase. The first step joins glutamate and cysteine to form gamma-glutamylcysteine and is generally rate-limiting. The second step adds glycine to complete the tripeptide. Cysteine availability, feedback inhibition by glutathione, and oxidative conditions influence flux through this pathway. The pathway is conserved across many organisms, and degradation by gamma-glutamyl transpeptidase and related peptidases recycles amino acids for new synthesis.
Cells synthesize glutathione through two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine, and glutathione synthetase adds glycine to form the complete tripeptide. Breakdown occurs through gamma-glutamyl transpeptidase and subsequent peptidase reactions, forming the gamma-glutamyl cycle. Within cells, glutathione also forms a disulfide-linked dimer called GSSG when two GSH molecules react. The balance between GSH and GSSG is widely used as an indicator of oxidative conditions, although the ratio can vary by compartment and tissue.
Glutathione supports several cellular processes beyond direct antioxidant action. It serves as a cofactor for glutathione peroxidase and glutathione S-transferase enzymes, which reduce peroxides and conjugate electrophiles, respectively. The molecule also acts as a reservoir of cysteine, an amino acid that can limit protein synthesis and redox signaling. In human nutrition, oral glutathione is sold as a supplement, but how much intact glutathione reaches tissues after ingestion remains an active research question. Clinical claims about supplementation are not uniformly supported by controlled trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Glutathione | Reduced form is abbreviated GSH |
| Chemical class | Tripeptide | Composed of glutamate, cysteine, and glycine |
| Molar mass | 307.32 g/mol | For reduced glutathione |
| CAS Registry Number | 70-18-8 | For reduced L-glutathione |
| Appearance | White crystalline powder | Typical solid reference material |
Glutathione participates in detoxification reactions, amino acid transport, and the maintenance of protein thiols. It serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. In research literature, altered glutathione status appears in studies of aging, infection, metabolic stress, and environmental exposure. Whether low glutathione is a cause, consequence, or marker of such conditions often remains unresolved. Direct measurement in blood or tissue provides a snapshot, but results depend on sample handling, timing, and the method used.
Glutathione is a small tripeptide made of glutamic acid, cysteine, and glycine. Its cysteine thiol group allows reversible oxidation and reduction, making it central to cellular redox chemistry. The reduced form, often abbreviated GSH, predominates inside most cells, while the oxidized disulfide form, GSSG, forms when two GSH molecules react. The ratio of GSH to GSSG is widely used as an indicator of oxidative stress in laboratory research, though it does not by itself diagnose a clinical condition.
Biosynthesis occurs in two ATP-dependent steps. The enzyme glutamate-cysteine ligase joins glutamate and cysteine, forming gamma-glutamylcysteine; glutathione synthetase then adds glycine to produce the complete tripeptide. Because the peptide bond from glutamate uses the gamma-carboxyl group, glutathione resists digestion by many ordinary peptidases. Tissues vary in synthesis capacity, and the liver generally contains high concentrations relative to many other organs. This uneven distribution contributes to organ-specific differences in redox buffering and affects how experimental results are interpreted across tissue types.
Glutathione supports detoxification by conjugating reactive electrophiles through glutathione S-transferases. The resulting conjugates are processed and exported, often after further metabolism. It also stores cysteine, transports amino acids across membranes through the gamma-glutamyl cycle, and assists in the maturation of iron-sulfur clusters and some prostaglandins. In plants, animals, and many microbes, the molecule appears in similar roles, but concentrations vary enormously between tissues. Liver, kidney, and red blood cells tend to contain high amounts, while blood plasma contains much less.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
Clinton. In October 2002 at the International Symposium on Chromatography in London, Klaus Mosbach was presented the Martin Gold Medal, at the Royal Society, for the year 2000, by the Executive Committee of the Chromatographic Society. It was awarded him "in recognition of his major contributions to the field of separation science over many years". Previous recipients of this award are inter alia F. Regnier (1993), C. Horvath (1994) and W.H. Pirkle (1990). Mosbach published more than 537 peer reviewed scientific articles and reviews with an H-Index of 77. Mosbach wrote and edited four volumes of methods in enzymology series on Immobilized Enzymes, by Academic press (44,132,133,134). In addition he has received and applied for 84 patents.
== Proteolysis == In order for a signaling event to occur, the Notch protein must be cleaved at several sites. In humans, Notch is first cleaved in the NRR domain by furin while being processed in the trans-Golgi network before being presented on the cell surface as a heterodimer. Drosophila Notch does not require this cleavage for signaling to occur, and there is some evidence that suggests that LIN-12 and GLP-1 are cleaved at this site in C. elegans. Release of the NICD is achieved after an additional two cleavage events to Notch. Binding of Notch to a DSL ligand results in a conformational change that exposes a cleavage site in the NECD. Enzymatic proteolysis at this site is carried out by a A Disintegrin and Metalloprotease domain (ADAM) family protease. This protein is called Kuzbanian in Drosophila, sup-17 in C. elegans, and ADAM10 in humans. After proteolytic cleavage, the released NECD is endocytosed into the signal transmitting cell, leaving behind only a small extracellular portion of Notch. This truncated Notch protein can then be recognized by a γ-secretase that cleaves the third site found in the TM domain.
== Effects on health == Obesity increases a person's risk of developing various metabolic diseases, cardiovascular disease, osteoarthritis, Alzheimer's disease, depression, and certain types of cancer. Depending on the degree of obesity and the presence of comorbid disorders, obesity is associated with an estimated 2–20 year shorter life expectancy. High BMI is a marker of risk for, but not a direct cause of, diseases caused by diet and physical activity.
==== Stereotactic surgery and radiosurgery ==== PET can also be used in image guided surgery for the treatment of intracranial tumors, arteriovenous malformations and other surgically treatable conditions.
Sources: en.wikipedia.org
== Interactions == Methamphetamine is metabolized by the liver enzyme CYP2D6, so CYP2D6 inhibitors will prolong the elimination half-life of methamphetamine. Methamphetamine also interacts with monoamine oxidase inhibitors (MAOIs), since both MAOIs and methamphetamine increase plasma catecholamines; therefore, concurrent use of both is dangerous. Methamphetamine may decrease the effects of sedatives and depressants and increase the effects of antidepressants and other stimulants as well. Methamphetamine may counteract the effects of antihypertensives and antipsychotics owing to its effects on the cardiovascular system and cognition respectively. The pH of gastrointestinal content and urine affects the absorption and excretion of methamphetamine. Specifically, acidic substances will reduce the absorption of methamphetamine and increase urinary excretion, while alkaline substances do the opposite. Owing to the effect pH has on absorption, proton pump inhibitors, which reduce gastric acid, are known to interact with methamphetamine. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans. Similarly, norepinephrine–dopamine reuptake inhibitors (NRIs) like methylphenidate and bupropion prevent norepinephrine and dopamine release induced by amphetamines and bupropion has been found to reduce the subjective and sympathomimetic effects of methamphetamine in humans.
In order for a protonated acid to lose a proton, the pH of the system must rise above the pKa of the acid. The decreased concentration of H+ in that basic solution shifts the equilibrium towards the conjugate base form (the deprotonated form of the acid). In lower-pH (more acidic) solutions, there is a high enough H+ concentration in the solution to cause the acid to remain in its protonated form. Solutions of weak acids and salts of their conjugate bases form buffer solutions.
=== Gas chromatography === When IMS is coupled with gas chromatography, common sample introduction is with the GC capillary column directly connected to the IMS setup, with molecules ionized as they elute from GC. A similar technique is commonly used for HPLC. A novel design for corona discharge ionization ion mobility spectrometry (CD–IMS) as a detector after capillary gas chromatography has been produced in 2012. In this design, a hollow needle was used for corona discharge creation and the effluent was entered into the ionization region on the upstream side of the corona source. In addition to the practical conveniences in coupling the capillary to IMS cell, this direct axial interfacing helps us to achieve a more efficient ionization, resulting in higher sensitivity. When used with GC, a differential mobility analyzer is often called a differential mobility detector (DMD). A DMD is often a type of microelectromechanical system, radio frequency modulated ion mobility spectrometry (MEMS RF-IMS) device. Though small, it can fit into portable units, such as transferable gas chromatographs or drug/explosives sensors. For instance, it was incorporated by Varian in its CP-4900 DMD MicroGC, and by Thermo Fisher in its EGIS Defender system, designed to detect narcotics and explosives in transportation or other security applications.
== Function == Thymosin α1 is an agonist for toll-like receptor 2 and toll-like receptor 9 on both myeloid and dendritic antigen-presenting cells, thereby stimulating the adaptive immune response. Thymosin α1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It has been found to enhance cell-mediated immunity in humans as well as experimental animals.
==== 2005–2021 ==== While through recent history most designer drugs had been either opioids, hallucinogens, or anabolic steroids, the range of possible compounds is limited only by the scientific and patent literature, and recent years have been characterised by a broadening of the range of compounds sold as designer drugs. These have included a wide variety of designer stimulants such as geranamine, mephedrone, MDPV and desoxypipradrol, several designer sedatives such as methylmethaqualone and premazepam, and designer analogues of sildenafil (Viagra), which have been reported as active compounds in "herbal" aphrodisiac products. Designer cannabinoids are another recent development, with two compounds JWH-018 and (C8)-CP 47,497 initially found in December 2008 as active components of "herbal smoking blends" sold as legal alternatives to marijuana. Subsequently, a growing range of synthetic cannabinoid agonists have continued to appear, including by 2010, novel compounds such as RCS-4, RCS-8, and AB-001, which had never been reported in the literature, and appear to have been invented by designer drug manufacturers themselves. Another novel development is the use of research ligands for cosmetic rather than strictly recreational purposes, such as grey-market internet sales of the non-approved alpha-melanocyte-stimulating hormone tanning drugs known as melanotan peptides.
Sources: en.wikipedia.org
GSH is the reduced thiol form, while GSSG is the disulfide-linked oxidized dimer. The GSH:GSSG ratio is used as a redox indicator, though the ratio can vary with sample handling and cell type.
Glutathione is present in many foods, including meats, poultry, fish, some vegetables, and fruits. Cooking, storage, and digestion affect the amounts available for absorption.
Yes, both enzymatic steps in glutathione synthesis consume ATP. The first step, catalyzed by glutamate-cysteine ligase, is usually rate-limiting.
It is a tripeptide of glutamic acid, cysteine, and glycine. The linkage between glutamate and cysteine uses the gamma-carboxyl group, which is unusual for peptides.